Cyproheptadine use in hepatocellular carcinoma

Area of Science:

• Oncology
• Pharmacology
• Public Health

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern.
• Limited evidence exists on Cyproheptadine (CY) effectiveness across different HCC stages and treatments.
• Large-scale, prospective studies comparing CY in HCC are lacking.

Purpose of the Study:

• To compare the effectiveness of Cyproheptadine (CY) in patients with varying stages of hepatocellular carcinoma (HCC).
• To evaluate CY's impact on survival rates across different therapeutic modalities for HCC.
• To investigate CY's role in HCC management based on disease stage and treatment approach.

Main Methods:

• A cohort study utilizing the Taiwan Cancer Registry Database (2002-2011).
• Inclusion of 70,885 patients diagnosed with HCC.
• Comparison of survival outcomes between patients who received CY and those who did not, stratified by treatment and HCC stage.

Main Results:

• CY use was associated with significantly decreased all-cause mortality in patients receiving palliative treatment across all HCC stages (I-IV).
• For patients receiving no treatment, CY monotherapy significantly reduced all-cause mortality in all HCC stages (I-IV).
• CY did not demonstrate a survival benefit for patients with clinical stage I-II HCC undergoing curative treatments.

Conclusions:

• Cyproheptadine (CY) may enhance survival for hepatocellular carcinoma (HCC) patients undergoing palliative care or receiving no treatment, irrespective of disease stage.
• CY does not appear to improve survival outcomes for early-stage (I-II) HCC patients receiving curative therapies.
• Further research is warranted to elucidate the precise role of CY in HCC management, particularly in palliative and non-treatment settings.